BRIEF-Linden Advisors LP Reports 9.9% Passive Stake In Maxeon Solar Technologies-February 2024-www.financetom.com

BRIEF-Linden Advisors LP Reports 9.9% Passive Stake In Maxeon Solar Technologies

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Linden Advisors LP Reports 9.9% Passive Stake In Maxeon Solar Technologies

Jul 9, 2024 9:29 AM

July 9 (Reuters) - Maxeon Solar Technologies Ltd ( MAXN )

* LINDEN ADVISORS LP REPORTS 9.9% PASSIVE STAKE IN MAXEON

SOLAR

TECHNOLOGIES LTD AS OF JULY 2 - SEC FILING

Further company coverage:

Previous page： Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump Next page： Morgan Stanley shareholders urged to vote against pay proposal by proxy adviser

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump

Apr 29, 2024

10:51 AM EDT, 04/29/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said Monday it has received a jury trial verdict of $34 million related to the patent-infringement case it filed in September 2021 against Alcon ( ALC ) in the US District Court for the District of Delaware. The eyecare technology company said that it has asserted that Alcon's...

Morgan Stanley shareholders urged to vote against pay proposal by proxy adviser

Apr 29, 2024

NEW YORK, April 29 (Reuters) - Morgan Stanley ( MS ) shareholders should vote against its proposal for executive pay at the bank's annual meeting on May 23, according to a recommendation by influential proxy adviser Glass Lewis. Former CEO James Gorman, who is now executive chairman, was awarded $37 million by the company's board, while the three candidates to...

Annovis' Alzheimer's treatment helps improve cognition in trial

Apr 29, 2024

April 29 (Reuters) - Annovis Bio ( ANVS ) said on Monday its Alzheimer's treatment showed significantly higher improvement in cognition in patients during a mid-stage trial. The company's drug buntanetap works by decreasing the production of amyloid beta protein, believed to be a hallmark of Alzheimer's, from the brain. Annovis plans to conduct a late-stage trial based on results...

--Supreme Court Reportedly Rejects Musk's Bid to Challenge Agreement with SEC

Apr 29, 2024

10:47 AM EDT, 04/29/2024 (MT Newswires) -- Price: 188.69, Change: +20.40, Percent Change: +12.12 ...